Opus Genetics, Inc. (IRD) - Total Liabilities
Based on the latest financial reports, Opus Genetics, Inc. (IRD) has total liabilities worth $34.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Opus Genetics, Inc. to assess how effectively this company generates cash.
Opus Genetics, Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Opus Genetics, Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Opus Genetics, Inc. Competitors by Total Liabilities
The table below lists competitors of Opus Genetics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Huati Lighting Tech
SHG:603679
|
China | CN¥702.39 Million |
|
Meter Instruments Co. Ltd
SHE:301006
|
China | CN¥189.00 Million |
|
Haibo Heavy Engineering Science and Technology Co Ltd
SHE:300517
|
China | CN¥394.38 Million |
|
Shanxi Tond Chemical Co Ltd
SHE:002360
|
China | CN¥2.58 Billion |
|
Palram
TA:PLRM
|
Israel | ILA564.43 Million |
|
ATN International Inc
NASDAQ:ATNI
|
USA | $1.03 Billion |
|
Agro Tech Foods Limited
NSE:ATFL
|
India | Rs1.33 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Opus Genetics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Opus Genetics, Inc. (IRD) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Opus Genetics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Opus Genetics, Inc. (2019–2025)
The table below shows the annual total liabilities of Opus Genetics, Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.90 Million | +15.78% |
| 2024-12-31 | $30.14 Million | +645.62% |
| 2023-12-31 | $4.04 Million | +46.82% |
| 2022-12-31 | $2.75 Million | -28.59% |
| 2021-12-31 | $3.85 Million | -87.62% |
| 2020-12-31 | $31.15 Million | +233.36% |
| 2019-12-31 | $9.34 Million | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more